Basilea Pharmaceutica Ltd. Logo
 

Oncology 2012

 
 
 

Research

24th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics, November 2012, Dublin, Ireland

  • 421 / Dual mechanism of action of the novel microtubule-targeting drug BAL27862 (active moiety of the prodrug BAL101553): targeting tumor and vascular cells. Bachmann F, Lane HA.
  • 422 / Antitumor activity of BAL27862 (active moiety of the prodrug BAL101553) is associated with the generation of short non-centrosomal microtubules. Rovini A, HonorĂ© S, McKay N, Bachmann F, Lane HA, Braguer D.

American Association of Cancer Research AACR Annual Meeting 2012, April 2012, Chicago, United States of America

  • 3795 / BubR1 function is required for the antiproliferative activity of the novel microtubule-targeting drug BAL27862 (active moiety of the prodrug BAL101553). Lane H, Burger K, Bachmann F, Tzankov A, Boutros M, Gilbert D.
 
Info